During the last session, Biora Therapeutics Inc. (NASDAQ:BIOR)’s traded shares were 1.55 million. At the end of the trading day, the stock’s price was $0.75, reflecting an intraday gain of 5.54% or $0.04. The 52-week high for the BIOR share is $6.20, that puts it down -726.67 from that peak though still a striking 25.33% gain since the share price plummeted to a 52-week low of $0.56. The company’s market capitalization is $132.85M, and the average intraday trading volume over the past 10 days was 1.21 million shares, and the average trade volume was 1.97 million shares over the past three months.
Biora Therapeutics Inc. (BIOR) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.50. BIOR has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.12.
Biora Therapeutics Inc. (NASDAQ:BIOR) trade information
Biora Therapeutics Inc. (BIOR) registered a 5.54% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 5.54% in intraday trading to $0.75 this Thursday, 08/04/22, hitting a weekly high. The stock’s 5-day price performance is 4.63%, and it has moved by 18.88% in 30 days. Based on these gigs, the overall price performance for the year is -60.11%. The short interest in Biora Therapeutics Inc. (NASDAQ:BIOR) is 17.91 million shares and it means that shorts have 8.86 day(s) to cover.
The consensus price target of analysts on Wall Street is $5.00, which implies an increase of 85.0% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $4.00 and $6.00 respectively. As a result, BIOR is trading at a discount of -700.0% off the target high and -433.33% off the low.
Biora Therapeutics Inc. (BIOR) estimates and forecasts
Statistics show that Biora Therapeutics Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Biora Therapeutics Inc. (BIOR) shares have gone down -50.00% during the last six months, with a year-to-date growth rate more than the industry average at 68.79% against 1.10. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to grow 90.20% this quarter and then jump 78.30% in the quarter after that. In the rating firms’ projections, revenue will decrease -99.60% compared to the previous financial year.
While earnings are projected to return 51.50% in 2022.
Biora Therapeutics Inc. is due to release its next quarterly earnings in September. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Biora Therapeutics Inc. (NASDAQ:BIOR)’s Major holders
Biora Therapeutics Inc. insiders own 10.42% of total outstanding shares while institutional holders control 29.76%, with the float percentage being 33.22%. Athyrium Capital Management, LP is the largest shareholder of the company, while 63 institutions own stock in it. As of Mar 30, 2022, the company held over 29.86 million shares (or 16.21% of all shares), a total value of $34.63 million in shares.
The next largest institutional holding, with 6.54 million shares, is of Neuberger Berman Group, LLC’s that is approximately 3.55% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $7.59 million.
Also, the Mutual Funds coming in first place with the largest holdings of Biora Therapeutics Inc. (BIOR) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. Data provided on Mar 30, 2022 indicates that Vanguard Total Stock Market Index Fund owns about 3.37 million shares. This amounts to just over 1.83 percent of the company’s overall shares, with a $3.91 million market value. The same data shows that the other fund manager holds slightly less at 1.62 million, or about 0.88% of the stock, which is worth about $1.88 million.